Status | Study |
RECRUITING |
Study Name: Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary Myelofibrosis Condition: Myelofibrosis Date: 2022-09-06 Interventions: PegINFa will be given once every 2 weeks by subcutaneous administration in the abdomen or thigh. |
Completed |
Study Name: Efficacy and Safety of Ruxolitinib in Patients With Myelofibrosis Condition: Myelofibrosis Date: 2022-05-23 Interventions: Drug: Ruxolitinib |
RECRUITING |
Study Name: Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm Condition: Myelofibrosis Date: 2021-08-24 Interventions: ten (10) doses of Mutant-CALR peptides with KLH as helper peptide (in the first vaccine only).Mutant-CALR vaccine will administered every 2 week |
Not yet recruiting |
Study Name: A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis Condition: Myelofibrosis Date: 2017-05-05 Interventions: Drug: Itacitinib Itacitinib se |
Recruiting |
Study Name: A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis Condition: Myelofibrosis Date: 2017-02-27 Interventions: Drug: Ruxolitinib Ruxolitinib |
Recruiting |
Study Name: Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis Condition: Myelofibrosis Date: 2016-09-30 Interventions: Other: Hematopoietic Stem Cell Transplant This observational study will compare outcomes of prospectivel |
Recruiting |
Study Name: Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis Condition: Myelofibrosis Date: 2016-08-26 |
Active, not recruiting |
Study Name: Study of Ruxolitinib for Patients With Myelofibrosis (MF) Condition: Myelofibrosis Date: 2016-05-20 Interventions: Drug: Ruxolitinib Participants |
COMPLETED |
Study Name: Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis Condition: Myelofibrosis Date: 2016-05-20 Interventions: Undergo follow-up assessment |
Recruiting |
Study Name: A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis Condition: Myelofibrosis Date: 2016-03-21 Interventions: Drug: INCB050465 Up to 3 oral |